At what enterprise value was LAGARRIGUE acquired in 2016?

You can find the full valuation details of LAGARRIGUE on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of LAGARRIGUE when it was acquired by ARDIAN / IXO PRIVATE EQUITY?

The exact EV/EBITDA multiple for LAGARRIGUE is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.4x. Join our community for free to access full valuation data and industry trends.

When was LAGARRIGUE acquired by ARDIAN / IXO PRIVATE EQUITY?

LAGARRIGUE was acquired by ARDIAN / IXO PRIVATE EQUITY in 2016.

What was the revenue of LAGARRIGUE at the time of the deal?

The revenue of LAGARRIGUE at the time of the deal is estimated to be in the range of 50M - 100M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the LAGARRIGUE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LAGARRIGUE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.ardian.com/fr/communiques-de-presse/ardian-entre-en-negociations-exclusives-pour-lacquisition-dune-participation

← DATABASE

Home Database Healthcare & PharmaLAGARRIGUE

09/2016

LAGARRIGUE acquired by ARDIAN & IXO PRIVATE EQUITY

FRANCE Life Sciences / Medical Devices / Implants & Prosthetics REV 50M - 100M EUR

Context

Ardian entered into exclusive negotiations to acquire a majority stake in Lagarrigue from Azulis Capital. The transaction allowed the management team to reinforce their equity stake. Historical minority investor iXO Private Equity reinvested, while Azulis Capital, Galia Gestion, and BNP Paribas Developpement fully exited. This deal marked the transition from a regional SME to a national leader with international ambitions. The roadmap focused on external growth and digital transformation.

Azulis Capital / Bnp Paribas Developpement / Galia had previously taken control of the company during an LBO in 2011.

LAGARRIGUE, which reported an EBITDA margin of LOGIN in 2016, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Based in Toulouse, Lagarrigue is a leading French provider of external orthopaedic devices (prosthetics and orthotics). The group specializes in custom-made solutions (95% of activity) for patients with disabilities. Under previous ownership, it tripled its size, expanding into Switzerland, Belgium, and Spain, and digitized its operations through software subsidiaries (Rodin 4D, Vorum).

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2016

2015

Other operations with LAGARRIGUE

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
04/2021	NAXICAP PARTNERS	LAGARRIGUE	FRANCE	Life Sciences	Naxicap Partners acquired a majority stake (~80%) in Groupe Lagarrigue from Ardian and iXO Private Equity. The management team reinvested to hold the remaining ~20%. Naxicap prevailed in a competitive auction process managed by Edmond de Rothschild Corporate Finance, beating out offers from IK Investment Partners and Cobepa. The transaction is financed through a unitranche debt facility (likely provided by ArcMont AM) combined with a PIK note (CIC Private Debt), including significant capex lines to fund future external growth.
05/2011	AZULIS CAPITAL / BNP PARIBAS DEVELOPPEMENT / GALIA	LAGARRIGUE	FRANCE	Life Sciences	Following an initial OBO three years prior (where debt was fully repaid), Lagarrigue completed a majority LBO led by Azulis Capital. The consortium, including BNP Paribas Developpement, Galia Gestion, and historical investor iXO PE, acquired approximately 80% of the capital. The operation marked the full exit of the founder, who sold his remaining 20% stake. The manager and key executives reinvested for the remaining 20%. The deal was structured conservatively with 70% Equity/Mezzanine and only 30% Senior Debt to allow headroom for acquisitions in a fragmented market.

REFERENCES

Revenue range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LAGARRIGUE by ARDIAN / IXO PRIVATE EQUITY are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: lagarrigue

Acquirer: ardian / ixo private equity